Intro
Post-treatment Lyme disease syndrome (PTLDS) describes persistent symptoms — including fatigue, pain, and cognitive difficulties — that continue for months after appropriate antibiotic treatment for confirmed Lyme disease.
It is recognised in clinical guidelines as a real post-infectious syndrome, distinct from ongoing active infection.
Key Points
- PTLDS occurs in a minority of people treated for Lyme disease
- Current evidence does not support ongoing active Borrelia infection in most cases
- Long-term or repeated antibiotic courses are not recommended — they do not show sustained benefit and carry real risks
- Management focuses on symptom control, function, and wellbeing
- Overlaps with other post-viral and post-infectious syndromes
Mechanisms
The exact cause of PTLDS remains unclear. Leading hypotheses include:
- Immune dysregulation — infection triggers an immune response that does not fully resolve
- Central sensitisation — persistent changes in how the nervous system processes pain and fatigue signals
- Residual tissue damage — inflammation during active infection may cause lasting local changes
- Overlap with other syndromes — PTLDS shares features with Long COVID and other post-viral syndromes
There is no confirmed single mechanism. Research is ongoing.
Management
There is no proven cure for PTLDS. Evidence-based management includes:
- Validating the patient’s experience — symptoms are real, even if the mechanism is uncertain
- Addressing sleep, pain, and mood — these often compound each other
- Pacing and graded activity — returning to activity gradually, tailored to individual tolerance
- Psychological support — CBT and other approaches can help function and quality of life
- Avoiding prolonged antibiotics — repeated antibiotic courses have not shown benefit and carry risks including C. difficile infection
Multidisciplinary care (GP, physiotherapy, psychology) often produces the best outcomes.
FAQ
Q: Does PTLDS mean the Lyme infection is still active? A: Evidence does not generally support ongoing active infection in PTLDS. It is classified as a post-infectious syndrome, not chronic active Lyme.
Q: Should I take long-term antibiotics for PTLDS? A: Current guidelines do not recommend this. Controlled trials have not shown sustained benefit, and prolonged antibiotics carry genuine risks.
Q: Are there biomarkers to diagnose PTLDS? A: No validated specific biomarkers currently exist. Diagnosis is clinical, made after documented and treated Lyme disease with exclusion of other causes.
Q: Will PTLDS go away on its own? A: Many people improve gradually over months to years. Some have more prolonged symptoms. Supportive care and pacing can help recovery.
Q: Is PTLDS the same as “chronic Lyme disease”? A: The term “chronic Lyme disease” is used differently in different contexts. PTLDS is the term used in evidence-based guidelines and refers specifically to post-treatment persistent symptoms without evidence of ongoing infection.